secwatch.observer — SEC 8-K summary
======================================

Issuer:     AVITA Medical, Inc. (RCEL)
CIK:        0001762303
Form:       8-K
Filed at:   2023-06-16T23:59:59+00:00
Accession:  0001193125-23-168182
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AVITA Medical names David O'Toole CFO; $450K salary, 150K options
-----------------------------------------------------------------

- David O'Toole appointed CFO effective June 15, 2023; brings 30+ years biotech/life sciences finance experience.
- Annual base salary of $450,000; eligible for performance bonus up to 40% of base (max 90% combined).
- Granted 150,000 stock options under 2020 Omnibus Plan vesting in 3 equal annual installments.
- On termination without cause: 12 months base salary plus health benefits, unvested options accelerated for 3 months.
- Most recently CFO of Opiant Pharmaceuticals (acquired by Indivior); previously CFO of Soleno Therapeutics.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1762303/000119312523168182/0001193125-23-168182-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1762303/000119312523168182/d522351d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-168182

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer